Gillian Jessurun (Treant Zorggroep, Scheper Hospital Emmen, The Netherlands) has enrolled the first patient in the investigator-initiated MASTER DAPT (Management of patients post bioresorbable polymer stent implantation with an abbreviated DAPT regimen) study, launching the global investigation.
Ivascular has announced the product range extension of its self-expandable stent, iVolution, to 200mm length, in various diameters.
A Sheffield healthcare company has announced a strategic ‘buy out’ from its parent company, BD (Becton, Dickinson and Company), a deal which will see the company independently trade once again as UK Medical Ltd.
A study recently published in Cardiovascular and Interventional Radiology has, for the first time, identified adenomatous-dominant benign prostatic hyperplasia as a predictor of clinical success following prostate artery embolization.
Mirabilis has announced CE mark authorisation to market the Mirabilis System in the European Union. The system combines high-speed therapeutic ultrasound technology with an advanced robotic system for uterine fibroid treatment.
Metactive, an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, has announced the issuance of US patents 9,572,697 and 9,572,698 covering its Blockstent Microcatheter for embolization of peripheral arteries and veins and Ballstent Microcatheter for embolization of cerebral aneurysms. These proprietary microcatheter devices deliver a compressed gold metal implant over a 0.014” guidewire to treatment sites, where the implant is expanded and then detached to permanently stop blood flow.
The new meta-analysis, presented as a poster by researchers from the University of Texas Health Sciences Center, San Antonio, USA, during the 2017 American College of Cardiology meeting on 19 March, included data from nine studies comparing the use of RenalGuard to conventional volume expansion. Six were randomised controlled trials using RenalGuard in the treatment of patients undergoing various cardiovascular diagnostic and therapeutic interventions. Primary outcomes in the analysis included the incidence of contrast-induced acute kidney injury and relative risk. Secondary outcomes included the incidence of mortality, major adverse cardiovascular events, and the need for post-procedure dialysis.
Venoplasty is not effective in treating multiple sclerosis, according to the first presentation of interim data from a randomised, double blind clinical trial of jugular and azygous venoplasty in multiple sclerosis. Lindsay Machan, University of British Columbia (UBC) and Vancouver Coastal Health, presented the data at the Society of Interventional Radiology’s annual scientific meeting in Washington, DC, USA.
Interventional radiologists at the University of California at Los Angeles (UCLA), Los Angeles, USA, are using technology found in self-driving cars to power a machine learning application that helps guide patients’ interventional radiology care, according to research presented today at the Society of Interventional Radiology’s 2017 annual scientific meeting (4–9 March, Washington, DC, USA).
Prostate artery embolization maintains its effectiveness for at least three years after patients undergo the therapy, according to research presented at the Society of Interventional Radiology’s 2017 annual scientific meeting. The study was awarded as the “Abstract of the Year”.
Isobar Compression has been awarded a research contract from the Small Business Research Initiative (SBRI) for Healthcare, to assist in a feasibly study in primary care for the treatment of venous leg ulcers.
Three-year outcomes from the VeClose US pivotal clinical trial and one-year data from the WAVES study have been presented at the 2017 CX Symposium in London, UK. Both results were presented by Kathleen Gibson (Bellevue, USA). The new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal closure system in treating patients with venous reflux disease.
Research published in Phlebology has indicated that the 2013 UK varicose veins clinical guidelines have led to “a considerable increase” in leg ulcer patient referrals, although many patients are still not being referred early enough, the authors of the paper argue.
Inari Medical, a venture capital backed medical device company focused on the interventional treatment of venous thrombus, has announced the treatment of the first patient with its ClotTriever thrombectomy system.
Further evidence has been found by researchers at the UK’s University of Leicester and University of Bristol to suggest statins could “significantly reduce” the occurrence of blood clotting in certain parts of the body.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos